% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{BlattnerJohnson:169858,
      author       = {M. Blattner-Johnson$^*$ and D. T. W. Jones$^*$ and E.
                      Pfaff$^*$},
      title        = {{P}recision medicine in pediatric solid cancers.},
      journal      = {Seminars in cancer biology},
      volume       = {84},
      issn         = {1044-579X},
      address      = {London},
      publisher    = {Academic Press},
      reportid     = {DKFZ-2021-01592},
      pages        = {214-227},
      year         = {2022},
      note         = {#EA:B360#LA:B360# / 2022 Sep;84:214-227},
      abstract     = {Despite huge advances in the diagnosis and treatment of
                      pediatric cancers over the past several decades, it remains
                      one of the leading causes of death during childhood in
                      developed countries. The development of new targeted
                      treatments for these diseases has been hampered by two major
                      factors. First, the extremely heterogeneous nature of the
                      types of tumors encountered in this age group, and their
                      fundamental differences from common adult carcinomas, has
                      made it hard to truly get a handle on the complexities of
                      the underlying biology driving tumor growth. Second, a
                      reluctance of the pharmaceutical industry to develop
                      products or trials for this population due to the relatively
                      small size of the 'market', and a too-easy mechanism of
                      obtaining waivers for pediatric development of adult
                      oncology drugs based on disease type rather than mechanism
                      of action, led to significant difficulties in getting access
                      to new drugs. Thankfully, the field has now started to
                      change, both scientifically and from a regulatory
                      perspective, in order to address some of these challenges.
                      In this review, we will examine some of the recent insights
                      into molecular features which make pediatric tumors so
                      unique and how these might represent therapeutic targets;
                      highlight ongoing international initiatives for providing
                      comprehensive, personalized genomic profiling of childhood
                      tumors in a clinically-relevant timeframe, and look briefly
                      at where the field of pediatric precision oncology may be
                      heading in future.},
      subtyp        = {Review Article},
      keywords     = {Genomics (Other) / Pediatric cancer (Other) / Precision
                      medicine (Other) / Targeted therapy (Other)},
      cin          = {B360},
      ddc          = {610},
      cid          = {I:(DE-He78)B360-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34116162},
      doi          = {10.1016/j.semcancer.2021.06.008},
      url          = {https://inrepo02.dkfz.de/record/169858},
}